New-Onset Focal Seizures in a Pregnant Patient
A 29-year-old woman, G1P0 at 22 weeks gestation, presents with two episodes of right arm jerking spreading to the face with preserved awareness, each lasting about 40 seconds, over the past 10 days. She has no prior seizure history. Neurologic exam is normal. She is on no medications except prenatal vitamins. MRI brain without contrast is normal. Routine EEG shows rare left frontocentral sharp waves. She is anxious about medication effects on the fetus and asks whether she can wait until after delivery to start treatment.
1. Should treatment be started now, and how do you frame the risk-benefit discussion?
Read the worked answer
Yes - she has recurrent unprovoked focal seizures with an epileptiform EEG, and the risk of a seizure (including a focal-to-bilateral tonic-clonic seizure with falls, injury, or status epilepticus) during pregnancy outweighs the risks of appropriately chosen medication. Uncontrolled generalized tonic-clonic seizures pose maternal and fetal risks (trauma, hypoxia, abruption). The discussion should be explicit: untreated seizures carry real risk; most modern antiseizure medications have low malformation risk, but no drug is zero-risk. Frame it as choosing the lowest-effective-risk agent at the lowest effective dose with monotherapy, plus folic acid supplementation, rather than deferring treatment.
2. Which agents are preferred and which should be avoided in pregnancy, and why?
Read the worked answer
For focal epilepsy, lamotrigine and levetiracetam are generally favored in pregnancy because of relatively favorable malformation data; carbamazepine is an alternative but has more interaction and teratogenicity concerns; valproate should be avoided (neural tube defects, neurodevelopmental harm). Topiramate carries oral cleft and low birth weight concerns. Critically, lamotrigine clearance rises substantially during pregnancy (especially second/third trimester), so levels fall and breakthrough seizures occur - monitor levels and increase dose proactively, then reduce postpartum to avoid toxicity. Levetiracetam clearance also increases in pregnancy and should be monitored. Start monotherapy at the lowest effective dose, supplement folic acid 5 mg daily, and plan therapeutic drug monitoring.
3. What monitoring and peripartum plan do you recommend?
Read the worked answer
Baseline and serial drug levels (especially if lamotrigine), with dose adjustments across trimesters and a planned postpartum dose reduction guided by levels. Anatomy ultrasound at 18–22 weeks (already due) and consider fetal echocardiography if on higher-risk agents. Coordinate with obstetrics for a delivery plan: continue medication through labor, monitor for seizures peripartum, and ensure neonatal team awareness. Counsel on sleep, hydration, and avoiding triggers. Discuss breastfeeding compatibility (lamotrigine and levetiracetam are generally compatible; monitor infant for sedation). Reassess seizure freedom and consider whether the focal semiology warrants longer-term imaging follow-up after delivery.